Refine
Year of publication
Document Type
- Article (62)
- Preprint (19)
- Conference Proceeding (1)
Language
- English (82)
Has Fulltext
- yes (82)
Is part of the Bibliography
- no (82)
Keywords
- antiviral therapy (6)
- neuroblastoma (6)
- cancer (5)
- drug resistance (5)
- ABCB1 (4)
- COVID-19 (4)
- SARS-CoV-2 (3)
- ABCC1 (2)
- ABCG2 (2)
- Chemotherapy (2)
- Drug resistance (2)
- HSV-1 (2)
- antiviral (2)
- antiviral drugs (2)
- apoptosis (2)
- cabozantinib (2)
- chemoresistance (2)
- cisplatin resistance (2)
- doxorubicin (2)
- drug release (2)
- growth inhibition (2)
- human cytomegalovirus (2)
- nutlin-3 (2)
- oncomodulation (2)
- p53 (2)
- penile cancer (2)
- poly(lactic-co-glycolic acid) (PLGA) (2)
- resistant cell lines (2)
- survivin (2)
- targeted therapy (2)
- 2-deoxy-d-glucose (1)
- 2019-nCoV (1)
- AKT (1)
- AZD7762 (1)
- Acquired drug resistance (1)
- Acquired resistance (1)
- Acute Myeloid Leukemia (AML) (1)
- Acute lymphoblastic leukemia (1)
- Acute lymphocytic leukaemia (1)
- Acute myeloid leukemia (1)
- Adhesion (1)
- Alisertib (1)
- Angiogenesis (1)
- Aurora kinase inhibitor (1)
- BIRC5 (1)
- BRVO (1)
- Biomarkers (1)
- Bladder cancer (1)
- CBA (1)
- CCL2 (1)
- CD47 (1)
- CDK inhibitor (1)
- CNDAC (1)
- Cancer (1)
- Checkpoint kinase (1)
- DCK (1)
- DOK1 (1)
- Drug resistance/synergy (1)
- Drug targets (1)
- FGFR (1)
- G207 (1)
- Gemcitabine (1)
- H5N1 (1)
- HCMV (1)
- HRas (1)
- HSV (1)
- HSV-2 (1)
- Hedgehog pathway (1)
- IAP (1)
- IL-6 (1)
- Intrinsic resistance (1)
- JNK3 (1)
- Leukemia (1)
- MCP (1)
- MDM2 (1)
- MK-0457 (1)
- MLN8237 (1)
- MTT assay (1)
- Melanoma (1)
- Metabolic models (1)
- Metabolic vulnerabilities (1)
- Mitosis (1)
- Mitoxantrone (1)
- N-acetyl-L-cysteine (1)
- NSC350625 (1)
- Nanoparticles (1)
- Neuroblastoma (1)
- ONC201 (1)
- Oncology (1)
- PEA-15 (1)
- PEGylated PLGA (PLGA-PEG) (1)
- PLX4032 (1)
- PLX4720 (1)
- PTK2B (1)
- RITA (1)
- SAMHD1 (1)
- SD-OCT (1)
- SIRPalpha (1)
- Sapacitabine (1)
- TIC10 (1)
- Tozasertib (1)
- Traditional Chinese Medicine (TCM) (1)
- Urothelial carcinoma (1)
- VEGF (1)
- VX680 (1)
- Vemurafenib (1)
- Vincristine (1)
- YK-4-279 (1)
- YM155 (1)
- acquired drug resistance (1)
- amygdalin (1)
- aprotinin (1)
- artesunate (ART) (1)
- authentication (1)
- autophagy (1)
- baicalein (1)
- benfooxythiamine (1)
- biochanin A (1)
- biomarker (1)
- biomarkers (1)
- bladder cancer (BCa) (1)
- bortezomib (1)
- c-MET (1)
- cabazitaxel (1)
- cancer cell malignancy (1)
- cancer drug (1)
- cell line (1)
- cell lines (1)
- cell proliferation regulating inhibitor of protein phosphatase 2A (1)
- cellular signalling (1)
- cervical cancer (1)
- chelator (1)
- chemotherapy (1)
- cilia (1)
- cisplatin sensitivity (1)
- coagulation (1)
- coagulopathy (1)
- complementary/alternative medicine (CAM) (1)
- coronavirus (1)
- docetaxel (1)
- docetaxel (DX) resistance (1)
- drug discovery (1)
- drug repurposing (1)
- eltrombopag (1)
- emulsion diffusion (1)
- epidermal growth factor receptor (1)
- herpes simplex virus type 1 (1)
- herpes simplex virus type 2 (1)
- human rhabdomyosarcoma (1)
- integrins (1)
- intrinsic drug resistance (1)
- iron chelation (1)
- isogenic (1)
- kaffir lime (1)
- kinase inhibitor (1)
- long-term infection (1)
- mTOR (1)
- marker (1)
- mass spectrometry (1)
- monkeypox (1)
- multi-drug resistance (1)
- nanoparticles (1)
- necroptosis (1)
- non-small cell lung cancer (1)
- orthopoxvirus (1)
- ovarian cancer (1)
- oxythiamine (1)
- p38 (1)
- p53 activator (1)
- pentose phosphate pathway (1)
- pirinixic acid (1)
- pirinixic acid derivative (1)
- polylactic acid (PLA) (1)
- poxvirus (1)
- prostate cancer (1)
- prostate cancer (PCa) (1)
- prostate carcinoma cells (1)
- proton pump inhibitors (1)
- radiation (1)
- reactive oxygen species (1)
- resistance (1)
- ribavirin (1)
- ribonucleotide reductase (1)
- severe acute respiratory syndrome coronavirus (1)
- severe acute respiratory syndrome coronavirus 2 (1)
- shikonin (SHI) (1)
- solvent displacement (1)
- squamous cell carcinoma (1)
- therapy monitoring (1)
- thrombopietin receptor agonist (1)
- thrombosis (1)
- tivantinib (1)
- transferrin (1)
- vincristine (1)
- vitreous samples (1)
Institute
- Medizin (81)
- Biowissenschaften (1)
- Erziehungswissenschaften (1)
- Exzellenzcluster Makromolekulare Komplexe (1)
- Pharmazie (1)
SARS-CoV-2 is causing the coronavirus disease 2019 (COVID-19) pandemic, for which effective pharmacological therapies are needed. SARS-CoV-2 induces a shift of the host cell metabolism towards glycolysis, and the glycolysis inhibitor 2-deoxy-d-glucose (2DG), which interferes with SARS-CoV-2 infection, is under development for the treatment of COVID-19 patients. The glycolytic pathway generates intermediates that supply the non-oxidative branch of the pentose phosphate pathway (PPP). In this study, the analysis of proteomics data indicated increased transketolase (TKT) levels in SARS-CoV-2-infected cells, suggesting that a role is played by the non-oxidative PPP. In agreement, the TKT inhibitor benfooxythiamine (BOT) inhibited SARS-CoV-2 replication and increased the anti-SARS-CoV-2 activity of 2DG. In conclusion, SARS-CoV-2 infection is associated with changes in the regulation of the PPP. The TKT inhibitor BOT inhibited SARS-CoV-2 replication and increased the activity of the glycolysis inhibitor 2DG. Notably, metabolic drugs like BOT and 2DG may also interfere with COVID-19-associated immunopathology by modifying the metabolism of immune cells in addition to inhibiting SARS-CoV-2 replication. Hence, they may improve COVID-19 therapy outcomes by exerting antiviral and immunomodulatory effects.